EspeRare to relaunch a therapeutic programme for XLHED, a rare and life-threatening disease

EspeRare to relaunch a therapeutic programme for XLHED, a rare and life-threatening disease

26.4.2018 EspeRare and Edimer Pharmaceuticals Inc. announced today that they have entered into an agreement for EspeRare to receive the full rights to continue the development of ER-004, an innovative therapy for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), a rare genetic disorder.

Read more…